Life Science Company News

Major shareholder announcement

June 21, 2024

Company announcement No. 22

Pursuant to Section 30 of the Danish Capital Markets Act, Novonesis hereby announces that Novo Nordisk Fonden has on its own behalf and on behalf of its wholly owned subsidiary Novo Holdings A/S notified Novonesis, that as of yesterday, Novo Nordisk Fonden and Novo Holdings A/S, indirectly and directly, respectively, holds a total of 53,743,600 A-shares (nominally DKK 107,487,200) and 65,672,555 B-shares (nominally DKK 131,345,110) corresponding to 25.50% of the entire issued share capital and 63.35% of the total voting rights in Novozymes A/S, part of Novonesis Group.

Contact information  
Tobias Bjorklund

+45 3077 8682

tobb@novonesis.com
 


Anders Enevoldsen

+45 5350 1453

adev@novonesis.com
 


Disa Tuominen

+45 6038 5826

ditu@novonesis.com
 

Attachment


By: GlobeNewswire - 21 Jun 2024
Back to overview

Enhance your business development with Biotechgate